Skip to main content

Table 3 Recorded ILD diagnoses in completed data sets (n = 705) up to 1st August 2019

From: Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database

ILD classification ILD diagnosis Total number of patients to 1st August 19
Idiopathic Interstitial Idiopathic Pulmonary Fibrosis (IPF) 240 (34%)
Pneumonias (IIP) Non-specific interstitial pneumonia (iNSIP) 29 (4.1%)
Desquamative Interstitial Pneumonia (DIP) 2 (0.3%)
Combined Pulmonary Fibrosis and Emphysema (CPFE) 30 (4.3%)
Cryptogenic Organising Pneumonia (COP) 14 (2%)
Lymphocytic Interstitial Pneumonia (LIP) 2 (0.3%)
Respiratory Bronchiolitis Associated ILD (RB-ILD) 9 (1.3%)
Acute interstitial pneumonia (AIP) 1 (0.1%)
Unclassifiablea 51 (7.2%)
ILD of known association Connective Tissue Disease associated ILD (CTD-ILD) 125 (17.7%)
Drug induced ILD 7 (1.0%)
Occupational exposures 11 (1.6%)
Granulomatous ILD Hypersensitivity Pneumonitis (HP) 66 (9.4%)
Sarcoidosis 44 (6.2%)
Vasculitis associated ILD 12 (1.7%)
Miscellaneous ILD Lymphangioleiomyomatosis (LAM) 2 (0.3%)
Langerhan’s cell histiocytosis (LCH) 1 (0.1%)
Other Early ILD – Interstitial Lung Abnormality 5 (0.7%)
Interstitial Pneumonia with Autoimmune features (IPAF) 3 (0.4%)
Pulmonary Alveolar Proteinosis 1 (0.1%)
Not ILDb 18 (2.6%)
Not specified 32 (4.8%)
  1. aDefined as < 50% diagnostic certainty of any diagnosis (Ryerson Classification)
  2. bIncludes patients initially managed as ILD with subsequent change in diagnosis